This week in therapeutics




Licensing status

Publication and contact information

Cardiovascular disease

Ischemia/reperfusion injury

Sirtuin 2 (SIRT2)

Mouse studies suggest inhibiting SIRT2 could help treat ischemia/reperfusion injury. In a mouse model of ischemia/reperfusion injury, Sirt2 knockout or an inhibitor of SIRT2 decreased necrosis and infarct size compared with no knockout or vehicle. Next steps include determining the time frame during which SIRT2 inhibitors have a therapeutic benefit in ischemia and testing whether modulating necrosis via SIRT2 inhibition could have benefit in other indications, such as neurodegenerative diseases.
Indus Biotech Pte. Ltd.'s SIRT2 inhibitor INDUS815B is in preclinical development for Parkinson's disease (PD) and renal disease. The company also has the SIRT2 inhibitor INDUS815C in discovery for Huntington's disease (HD) and ophthalmic indications.

SciBX 6(1); doi:10.1038/scibx.2013.12
Published online Jan. 10, 2013

Patent application filed; available for licensing or partnering

Narayan, N. et al. Nature; published online Nov. 28, 2012;
Contact: Toren Finkel, National Institutes of Health, Bethesda, Md.